NW
GSK icon

NewEdge Wealth’s GSK GSK Stock Holding History

NewEdge Wealth’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.56M Buy
67,950
+1,410
+2% +$74.6K 0.04% 318
2026
Q1 		$3.67M Sell
66,540
-13,559
-17% -$735K 0.04% 281
2025
Q4 		$3.93M Buy
80,099
+2,096
+3% +$97.8K 0.04% 290
2025
Q3 		$3.64M Buy
78,003
+13,785
+21% +$538K 0.05% 264
2025
Q2 		$2.41M Buy
64,218
+6,199
+11% +$237K 0.04% 342
2025
Q1 		$2.25M Buy
58,019
+7,009
+14% +$257K 0.04% 333
2024
Q4 		$1.73M Buy
51,010
+9,613
+23% +$346K 0.03% 383
2024
Q3 		$1.69M Buy
41,397
+2,111
+5% +$86.4K 0.03% 376
2024
Q2 		$1.51M Buy
39,286
+229
+0.6% +$9.63K 0.03% 356
2024
Q1 		$1.69M Sell
39,057
-279
-0.7% -$11.5K 0.04% 353
2023
Q4 		$1.46M Sell
39,336
-1,044
-3% -$37.5K 0.04% 342
2023
Q3 		$1.46M Sell
40,380
-20
-0% -$710 0.05% 306
2023
Q2 		$1.44M Buy
40,400
+5,117
+15% +$184K 0.05% 304
2023
Q1 		$1.26M Buy
35,283
+5,751
+19% +$201K 0.05% 286
2022
Q4 		$1.04M Sell
29,532
-963
-3% -$32.1K 0.04% 285
2022
Q3 		$897K Buy
30,495
+2,335
+8% +$88.5K 0.04% 281
2022
Q2 		$1.53M Buy
28,160
+18,573
+194% +$1.03M 0.07% 225
2022
Q1 		$522K Buy
9,587
+5,028
+110% +$273K 0.02% 297
2021
Q4 		$251K Buy
+4,559
New +$237K 0.01% 361

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

NewEdge Wealth's GSK Position: Q2 2026 in Review

NewEdge Wealth increased its GSK (GSK) stake by 2.1% in Q2 2026, buying an estimated $74.6K and bringing the position to 67,950 shares worth $3.56M. The position accounts for 0.04% of the portfolio, ranked #318.

NewEdge Wealth first reported a position in GSK in Q4 2021 and has held it in 19 quarters since. The position peaked at $3.93M in Q4 2025. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • NewEdge Wealth held 67,950 shares of GSK worth $3.56M as of Q2 2026.
  • NewEdge Wealth bought 1,410 GSK shares in Q2 2026, an estimated $74.6K.
  • GSK made up 0.04% of NewEdge Wealth's portfolio in Q2 2026, its #318 holding.
  • NewEdge Wealth first reported a position in GSK in Q4 2021 and has held it in 19 quarters since.
  • NewEdge Wealth's GSK position peaked at $3.93M in Q4 2025.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on NewEdge Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.